Clinical trial · Interventional
Clinical Study of Weifuchun Treatment on Gastric Cancer
Randomized Clinical Trial:Clinical Study of Weifuchun Treatment on Gastric Cancer
NCT05888675CI-TRIAL-00068244completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Research purpose To elucidate the effect mechanism and clinical effective of weifuchun in the prevention and treatment of gastric cancer. From genes related to cell differentiation, proliferation, apoptosis, tumor invasion and metastasis, genes related to immune inflammation and immune escape and other possible aspects to elucidate the effective and mechanism of weifuchun's treatment on gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer (Diagnosis) | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Weifuchun | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Clinical Study of Weifuchun Treatment on Gastric Cancer
- description
- 72 patients with gastric cancer were randomly divided into a treatment group of 36 cases and a control group of 36 cases. The treatment group received combination chemotherapy with Weifuchun tablets, while the control group received monotherapy chemotherapy.
- interventionNames
- Drug: Weifuchun
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- the patients' were included into the clinical trials and up to 24 weeks treatment.
- description
- To observe the effects of treatment group and control group on OS in patients with advanced gastric cancer, and evaluate whether there is statistical difference in OS between the two groups.From date of randomization until the date of death from any cause, whichever came first, assessed up to 24 months.
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients should be aged between 18 and 70 years old (including 18 and 70 years old) and their gender is not limited. 2. Pathological diagnosis of gastric malignant tumor; 3. The pathological types were adenocarcinoma, tubular adenocarcinoma, mucous adenocarcinoma and sig-ring cell carcinoma (including adenocarcinoma and some sig-ring cell carcinoma); 4. Patients were willing to receive chemotherapy (oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, or Ticeo monotherapy regimen). 5. The patient was willing to receive weifunchun treatment. Exclusion Criteria: 1. Incomplete pathological diagnostic data; 2. Patients with severe heart, lung, liver, kidney (creatinine greater than the upper limit of the normal range), endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group; 3. Pregnant or lactating women, as well as pregnant persons who may not have taken effective contraceptive measures; 4. People who are allergic (allergic to two or more kinds of food, drugs, etc.) or are allergic to known ingredients of the medicine; 5. Patients with other medical conditions that interfere with the trial and are deemed unsuitable for inclusion in the trial by the investigator; 6. Patients enrolled in other clinical trials within the last 1 month.
References
Publications (0)
Data not yet available
No reference posted for this study.